Androgen receptor suppresses lung cancer invasion and increases cisplatin response via decreasing TPD52 expression
International Journal of Biological Sciences · 2023
DOI: 10.7150/ijbs.84577 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Biological Sciences, 2023. Verfasst von Shiqing Liu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Medicine, Xiangya Hospital, Central South University, Changsha, 410008, China. Hauptthemen laut MEDLINE: Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, MicroRNAs. Die Arbeit wurde bisher 19-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Lung cancer, as the most commonly diagnosed malignancy, still accounts for the leading cause of cancer-related deaths worldwide. The high rate of mortality and tumor recurrence has prompted clinicians and scientists to urgently explore new targets for improved treatment. Previous studies have indicated a potential role of the androgen receptor (AR) in the progression of non-small cell lung cancer (NSCLC). However, the precise mechanisms underlying this association, particularly its relation to TPD52-mediated cell invasion and cisplatin (DDP) response, have not been fully elucidated. Therefore, further investigation is necessary to gain a better understanding of these mechanisms and their potential implications for lung cancer treatment. In this study, we discovered that AR can suppress NSCLC cell invasion and increase cisplatin response by downregulating the expression of circular RNA (circRNA), specifically circ-SLCO1B7. This suppression is achieved through the direct binding of AR to the 5' promoter region of the host gene SLCO1B7. The decreased expression of circ-SLCO1B7, mediated by AR, released miR-139-5p back to the RISC (RNA induced silencing complex), where it bonds to the 3' untranslated region (3'UTR) of Tumor Protein D52 (TPD52) messenger RNA, resulting in TPD52 reduction. The in vivo data also validated the functional contribution of AR/circ-SLCO1B7/miR-139-5p/TPD52 axis to lung cancer progression. Furthermore, analysis of human NSCLC databases and clinical specimens confirmed the association of the AR/circ-SLCO1B7/miR-139-5p/TPD52 signaling pathway with NSCLC progression. Collectively, the results from our study suggest that AR can suppress lung cancer cell invasion and increase DDP response by modulating the circ-SLCO1B7/miR-139-5p/TPD52 signaling pathway. Targeting this novel signaling pathway may be a new therapeutic strategy to effectively constrain NSCLC development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Respiratory Medicine, Xiangya Hospital, Central South University, Changsha, 410008, China.
- Xiangya Lung Cancer Center, Xiangya Hospital, Central South University, Changsha, 410008, China.
- National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, 410008, China.
- Department of Thoracic Surgery, Xiangya Hospital, Central South University, Changsha, 410008, China.
- Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Southwest Medical University, Luzhou 646000, China.
- Department of General Surgery, Xiangya Hospital, Central South University, Changsha, 410008, China.
Zitieren
APA
Liu, S., Hu, C., Li, M., Zhou, W., Wang, R., & Xiao, Y. (2023). Androgen receptor suppresses lung cancer invasion and increases cisplatin response via decreasing TPD52 expression. International Journal of Biological Sciences. https://doi.org/10.7150/ijbs.84577
Vancouver
Liu S, Hu C, Li M, Zhou W, Wang R, Xiao Y. Androgen receptor suppresses lung cancer invasion and increases cisplatin response via decreasing TPD52 expression. International Journal of Biological Sciences. 2023. doi:10.7150/ijbs.84577
BibTeX
@article{Liu2023,
author = {Liu, Shiqing and Hu, Chengping and Li, Min and Zhou, Wolong and Wang, Ronghao and Xiao, Yao},
title = {Androgen receptor suppresses lung cancer invasion and increases cisplatin response via decreasing TPD52 expression},
journal = {International Journal of Biological Sciences},
year = {2023},
doi = {10.7150/ijbs.84577}
}
EUVIMED